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Congressman
Barney Frank to Speak
in Portland I
Art Auction Raises
Funds for TAP

PRO.JECT

by Demetra Giatas
TAP Development Director

Massachusetts Congressman Barney Frank, an openly
gay member of the U.S. House of Representatives, is coming to
Portland on Saturday, April 24th to speak at the launching of an
annual event called "The Frannie Peabody Lecture Series",
which is a collaborative fundraising event to benefit The AIDS
Project, Peabody House, and the AIDS Lodging House.
The lecture will be held at First Parish Church at 425
Congress Street in Portland. The lecture begins at 7 :30 p.m. and a
champagne and dessert reception follows at 8:45 p.m. For more
information or to buy tickets, please call TAP at 77 4-6877
And, thanks to the wonderful support of the community,
artists, committee members, volunteers and, of course, the
attendees and art purchases at the Spring for Life Art Auction in
March. The Auction raised gross receipts of $90,000 -- a record
amount!
Many thanks to everyone for their hard work and support!
'"'A~
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BYTHEWAY
Let me start with an apology. I'm sorry that the
size of the type in much of this issue is kind of small.
Each month I put together a file folder that holds all the
information I think will be of interest to our readers.
Some months it seems a little thin; other months, like this
one, it is overflowing with good stuff. So, I have to
decide. Bigger print and fewer stories or smaller print
and more stories? My bias is always to go with more
news and information. So grab onto your magnifying
glasses and read away.
Several weeks ago, The AIDS Project held its
annual Spring for Life Art Auction. As always, it was a
phenomenal event. When I think of the talent behind the
many pieces of art, the time and energy it takes to plan
the event, and the logistics of moving the art, I am
overwhelmed. But, as before, everything came off
without a hitch and a tidy sum of money was raised to
benefit TAP and its clients. Let me echo Demetra
Giatas's comments (on page one) to say, "Well done,
everyone!Andthankyousoverymuch."
In the past month I've talked to a few people
living with HIV about their management of their disease
with the combination drug therapies. In almost equal

by Mike Martin
numbers, they reported either great results or disappointment. These conversations simply reinforce my perception that the new drugs are not the total panacea we want
them to be. A couple of the news items in this newsletter
comment on research into the side effects of these new
drugs, research that has followed people who have been
taking the drugs for some time now. For the first time, I
have detected a real note of caution in the medical
community about when to begin treatment and whether
or not some of the side effects have greater immediate
harmful consequences than the virus itself.
The other thing I heard in my conversations, and
which I feel myself, is that the decision on what drugs to
take is not an easy one. With more and more drugs now
available, each with its own set of side effects to consider, it is now harder to decide, or to even know, what
combination is best to take. And I also heard from some
friends that when the drugs stop working, viral loads
seemtoreallyincreaserapidly(andthat'snotgood).
On the plus side, we have more options, more
choices. The trick now is to learn what seems to work
best. It is a process that people with HIV are learning "as
they go" in the life of their disease.

~
~,~------------------------

Immediate Seating Update
from Daniel Schnorbus, TAP's Client Services Coordinator

There will now be another way to access tickets from the "Immediate Seating" program at The AIDS
Project. Simply cut out and fill in this coupon and TAP will call you if tickets that match your interests
become available. So, please fill out the coupon completely and then mail it or drop it off at"
The AIDS Project
Attention: Daniel Schnorbus
625 Congress Street (if in person)
P.O. Box 5305 (if by mail)
Portland, Maine 04101
Your Name_ _ _ _ _ _ _ _ _ _ _ _ _ _Daytime Phone_ _ _ __
Address_ _ _ _ _ _ City_ _ _ _ _ State__Zip Code_ _ __
May we leave a message at your phone number? Yes__ No__
Areas of Interest:
Musical Events
Theater Events

_Sports Events
TAP Functions

Movies
Other

/i:m
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HIV Drug News

HIV Drug News

HIV Vaccine News

A Contraceptive Returns to the Market
New York Times (03/30/99)

HIV Drug Treatment Successes and Failures
Lancet (03/13/99)

U.N. AIDS Chief Says No Vaccine for At Least 10 Years
Fox News Online (03/17/99)

The contraceptive sponge will return to the U.S. market
after being pulled in 1995. The device, once the most
popular non-prescription birth control devices for women,
will be manufactured and marketed by Allendale
Pharmaceuticals, which bought the rights to the product
from American Home Products. Contraceptive sponges
have not been shown to protect against sexually
transmitted diseases, although the spermicide used in the
product may confer some protection against them.

The Swiss HIV Cohort conducted a study of 2,674 HIVinfected patients receiving highly active antiretroviral
therapy (HAART) and found that the subjects had a high
rate of virological failure, but a low rate of clinical
progression to AIDS. Of those treated, over 90% achieved
undetectable viral loads by one year; pre-treated patients
had lower rates of undetectable viral levels. Viral rebound
was seen in about one-fifth of treatment-naive patients
after two years at undetectable viral levels, and up to 40%
of pre-treated patients. After 30 months, about 6.6% of
patients who had undetectable viral levels, 9% of those
who showed viral rebound, and 20.1 % of patients who
never reached undetectable viral levels progressed to
AIDS or died.
The authors note that a second regimen was often
required in patients on HAART due to the high rate of
virological failure. They recommend that ''virological and
immunological responses should be assessed before
HAART is taken to be failing and the regimen is modified,
especially because the number of available treatment
options is limited." They further suggest controlled trials
to determine the optimum initiation point for HAART.

The head of the Joint U.N. Program on HIV/AIDS, Dr.
Peter Piot, said Wednesday that an HIV vaccine will not be
available for at least 1O more years. Piot added that
prevention is the only current option available for reducing
the spread of the virus, which infects 35 million people
worldwide. Piot also noted that the disease is increasingly
affecting young people and that ''there's still far too little
attention given to AIDS."
UNAIDS is trying to increase this year's HIV-prevention
efforts in Africa; Zimbabwe, Swaziland, Botswana,
Namibia, and South Africa are estimated to have 25 percent
to 33 percent of their adult populations infected with the
virus. HIV is also expected to cause a significant decline in
the life expectancy of these populations, resulting in
economic problems.

Glaxo Gets FDA Approval to Add Claims for AIDS-Drug
Wall Street Journal (03/25/99)
The FDA has approved measures allowing the U.S. unit of
Glaxo Wellcome to extend marketing claims for its anti-HIV
drug Epivir, also known as 3TC. Glaxo Wellcome announced
that the FDA will allow the marketing of the drug in a liquid
form for infants and children, and in an oral form for
adolescents. Glaxo Wellcome will also be allowed to market
3TC for use in combination with other anti-HIV medications.
The drug is one of the more commonly prescribed anti-HIV
medications already often used in combination therapy.
HCFA Mandates Medicaid Reimbursement
of Drug for AIDS Wasting
Reuters Health Information Services (04/06/99)
A press release from the National Association for People
With AIDS states that the Health Care Financing
Administration is requiring all states to provide Medicaid
reimbursement for the recombinant human growth
hormone Serostim, a treatment for AIDS wasting. The
decision reverses a previous HCFA ruling that allowed
states to refuse Medicaid coverage for the drug, classifying
it as atreatment for cosmetic weight gain.
Vaginal Creams Can Cause Condom Failure
Reuters Health Information Services (03/30/99)
Certain vaginal creams can cause condom failure, report
researchers from Baylor College of Medicine in Houston.
The scientists exposed 20 condoms to 10 over-the-counter
vaginal creams for five minutes each, observing that
condoms exposed to products with vegetable or mineral
oils took less time to burst when inflated with air. The
researchers, who report their findings in the Southern
Medical Journal, note that vaginal products containing
vegetable or mineral oils may be associated with decreased
condom integrity. They advised women using over-thecounter vaginal products containing the substances to use
caution.
Abbott Asks FDA to Approve New Form of AIDS Drug
Reuters (03/31/99)
Abbott Laboratories Wednesday submitted an
application to the FDA seeking permission to produce a new
capsule form of its AIDS drug Norvir, which has been in
limited supply because of problems related to production.
Abbott indicated it began work on the soft-gel capsule form
after production problems last September forced some
consumers using the drug to switch to a liquid form.
Although the drug maker said it could not determine when it
would get regulatory approval, it said patients would still
have access to the liquid form.

Cost as a Barrier to Condom Use:
American Journal of Public Health (04/99)
The cost of condoms can act as a barrier to use,
according to a study by Louisiana researchers. The study
recruited 195 of over 1,000 businesses distributing free
condoms, replacing the free condoms with low-cost
condoms (25 cents). Pre-and post-test surveys measured
condom use among participants reporting two or more
sexual partners. The percentage of respondents who
obtained condoms through the businesses dropped from
57% to 30% after the 25-cent charge was introduced. The
percentage of people reporting condom use during their
last sexual encounter fell from 77% to 64% after the
introduction of the charge. The authors conclude that ''free
condoms should be distributed to encourage their use by
persons at risk for HIV and other sexually transmitted
diseases."
Program Increases HAART Adherence in HIV Patients
AIDS Alert (03/99)
A pilot program at a Rhode Island hospital appears to
increase highly active antiretroviral therapy adherence
rates. Thus iar, only one month of the six-month project,
which involves patients who were referred by physicians
because of compliance problems, has been studied;
however, the results show potential. At baseline, 75% of
the patients said they had missed a dose of their regimen
within the previous four days; but after one month of the
program, only 22% said they had missed a dose.
Enrolled patients have their medications brought to
them weekdays by peer outreach workers, who watch
them take the morning dose and also check to see if the
previous day's treatments had been taken. The workers
also leave daily pill packets for the weekends. In all, the
program cost less than $40,000 for the first six months
and has grown to 23 patients from the original nine. As
patients progress in the program, medications are taken to
them on a less frequent basis. However, if the patient
appears to be having problems, the number of visits will be
increased.

Trials of Local HIV Vaccine to Begin
Age Online (03/29/99)
The Australian National Council on AIDS and Related
Diseases recently determined that a number of possible
Australian-produced vaccines against HIV are ready for
future development and could enter phase I trials within the
next few months.
Trials involving human subjects could begin as soon as
next year. Even though the trials are likely to be given fasttrack status, the chairman of the council's clinical trials and
treatment advisory committee said that a vaccine against
the virus would probably not be available for seven to 10
years. Preventive and therapeutic vaccines will both be
considered, and trials will be undertaken in both developed
and developing nations.
First Trial of HIV Vaccine Begins in Thailand
Reuters (03/24/99)
HIV vaccine trials will begin today in Thailand, with six
volunteers receiving their initial inoculations. The subjects
all use injection drugs and are the first of 2,500 people in the
country to be involved in the three-year clinical trial. Half of
the subjects will receive the vaccine, while the other half
will be given placebo. The vaccine was developed by
VaxGen in the United States and is designed to confer
resistance against the HIV strain prevalent in Thailand, the
rest of Asia, and the Pacific Rim.
Drug Makers Still Reluctant to Invest in HIV Vaccine
Albany Times Union Online (03/14/99)
The Pharmaceutical Research and Manufacturers of
America reports that pharmaceutical companies are
currently investigating 101 new drugs for HIV-infected
individuals. However, the firms are supporting only 12
experimental vaccine proposals, and only VaxGen's AIDS
vaccine has received Food and Drug Administration
approval for large-scale human testing.
According to Dr. Peggy Johnston, the assistant director
for AIDS vaccines at the National Institute for Allergy and
Infectious Diseases, drug firm executives are concerned
that too little is known about how HIV functions to justify
significant investment.
Other problems include the various strains of HIV and the
fact that the average vaccine costs $100 million to develop,
although the totals for an HIV vaccine could be much higher
and the completion date much further off.
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Treatment Issues for HIV-Positive Adolescents
AIDS Clinical Care (03/99)

Low Cardioraspiratory Fitness in HIV+ leans
Reuters Health Information Services (03/29/99)

Students Believe Pill Can Stop AIDS
UK Independent Online (03/13/99)

HIV infection in adolescents may have different features
compared to infection in adults. The Reaching for
Excellence in Adolescent Care and Health (REACH) study is
currently investigating infection differences found in
younger patients. Initial findings indicate that adolescents
may have a greater potential for immune reconstitution due
to the presence of residual thymic tissue. Other studies
show that most youth acquired their infection through
sexual transmission during adolescence and begin care
when asymptomatic, with moderate immune dysfunction.
Perinatally infected children who survive to adolescence
often have advanced disease.
According to the Montefiore Adolescent AIDS Program,
there are four primary issues that HIV-infected youth need
to address in coping with their health status: receiving an
HIV diagnosis, disclosing status to family and others,
coping with illness, and preparing for death. Infected
adolescents may have problems with mental illness and
substance abuse, both of which are important comorbidities for HIV-positive youth. These problems should
be identified and addressed in patients to help them
successfully cope with their disease and for the
maintenance of antiretroviral adherence. Providers should
be aware of the local legal issues in regard to the treatment
of adolescents with sexually transmitted diseases. For
routine health care, HIV-positive adolescents should be
routinely screened for other STDs, while tuberculosis
screening should be performed according to guidelines in
place for HIV-infected adults.
Pharmokinetics may differ in adolescents, and
antiretrovirals may have interactions with commonly
prescribed medications in younger patients. The AIDS
Clinical Trials Group is currently undertaking measures to
institute adolescent-relevant trials to improve treatment
measures for infected youth.

Researchers at the University of Maryland in Baltimore
report that many HIV-infected teenagers have poor
cardiorespiratory capacity. The researchers concluded
that HIV-infected adolescents may have diminished
physiological capabilities that may limit them to light
physical activity. The study focused on nine HIV-positive
teens who received combination therapy. The subjects
reported low energy levels but were unaware thatthe their
fatigue was caused by their HIV status.

New research into the sexual knowledge of British youth
indicates large gaps. The "Young People and Health" survey,
which involved more than 10,000 11- to 16-year-olds,
revealed that only 39 had heard of gonorrhea, one-third of
syphilis, and 51 percent of herpes. More than 25 percent
believe the contraceptive pill will guard against STDs. The
study also found that the teens want more information
about AIDS.

Beyond AIDS: Taanagers and sm•s
Washington Post (03/23/99)

'The Talk' With Kids Should Occur Early, Often
Washington Post (04/06/99)

Many teenagers in the U.S. are informed about the
dangers of HIV, but they are often unaware of many other
common sexually transmitted diseases. A recent national
survey of 15-17 year olds found that they seriously
underestimated their risk of contracting STD's other than
HIV. About one-third of the respondents who were
sexually active felt they were at risk for acquiring an STD,
and few had been tested for infection. Less than half knew
that herpes and human papillomavirus have no known
cure or that gonorrhea and syphilis can be cured.
Teens are at a higher risk for contracting STD's
compared to many other groups, with three-fourths of
non-HIV STD's occurring in people aged 15 to 24. Many
infected people are asymptomatic and unaware that they
have an STD. STD's can later result in cancer, infertility,
neurological diseases, and death.
The CDC's Dr. Helene Gayle explains that ''we as a
society have not talked openly about STD's. There are
severe consequences, particularly for young women." In
addition to health issues, Gayle notes that STD's other
than HIV cost about $8 billion a year to diagnose and treat.

A new survey funded by the Kaiser Family Foundation
and Children Now indicates that talking about sex with their
children is still hard for parents. Kaiser's Tina Hoff notes that
the issue is difficult, "but once you break this barrier, you
have really crossed a communication line."
The study found that nearly 50 percent of parents of 1Oto 12-year-olds have not broached the topic of how to deal
with peer pressure to have sex, and 60 percent of parents
have not discussed pregnancy and sexually transmitted
disease prevention. However, according to the survey, preteens are likely to be open to the information; almost 40
percent of 10- to 12-year-olds report that their peers get "a
lot" of AIDS, sex, drugs, and alcohol information from their
mothers. An equal percentage reported obtaining
information from television/movies and schools/teachers.
Over 60 percent of 13- to 15-year-olds reported friends and
television/movies as the primary information sources,
followed by schools and teachers, the Internet, and
mothers, respectively. New York parenting expert Lynne S.
Dumas notes that sex education should be an on-going
discussion, not just a one-time conversation.

Need a home for unused medications? The folks at AID for AIDS has an idea. They are often asked if they can
forward unused medications to clients who need them. For legal reasons, they must so "no". But, before you
throw those medications away, consider mailing them! AID for AIDS is a non-profit organization that
distributes HIV medications and information to Latin America. They provide a life-saving service to people
who would not ordinarily have access to HIV meds. Currently, AID for AIDS has a waiting list of over 30
people who need all types of medications. You can send meds you no long use to:

The AIDS Project
615 Congress Street - 6th Floor
(or 142 High Street)
P.O. Box5305
Portland, Maine 04101
Phone: 774-6877 Fax: 879-0761
E-mail: tap@aidsproject.org
Website : www.aidsproject.org
AIDS Hotline: 775-1267
or 1-800-851-2437
York County Office
Lafayette Center - 4th Floor
Kennebunk, ME 04043
Phone: 985-8199
Fax: 985-8646 *51
E-mail : tap2@mail.javanet.com
Staff:
Doug Bailey,
HAVEN I Housing Coordinator
Declan Buckley,
MSM Outreach Worker
Diana Carrigan ,
Cumberland County Case Manager

~
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Janine Collins,
Cumberland County Case Manager
John Cronin,
MSM Outreach Worker
Carolyn Curtis,
Case Management Intern
Sequoia Dance,
Street Outreach Worker
Douglas Eaton,
Program Coard. of HIV Prevention
Denise Ferer,
York County Case Mngmt. Intern
Jill Frame,
HAVEN Case Manager
George W. Friou,
Executive Director
Demetra Giatas,
Development Director
John Green,
HIV Case Manager
John Holverson,
Director of Prevention and Education
Gloria Leach ,
Community HIV Prevention Educator

J
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AID for AIDS
P.O. Box 1862, Old Chelsea Station
New York, NY 10113
Or call AID for AIDS at 212-358-9715

Nicole Lebrecque,
Intern
Annette Lemek,
Case Management Intern
Randy May,
Director of Support Services
Rebecca Neel,
Cumberland and York Counties
Case Manager
Susan Parr,
Cumberland County Case Manager
Getty Payson,
York County Case Manager
Steve Reevy,
Manager I Finance & Administration
Daniel Schnorbus,
Client Services Coordinator
Gerry Scoppettuolo,
York County Field Outreach Worker
David Aaron Swander,
Education I Development Assistant
Kerry S. Tardiff,
Administrative I Case Management Assistant
Art Waller,
Accounting Assistant
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HIV and Needles

Cash Changes Sex Ed Doctrine
Washington Post (04/05/99)

Needle Exchanges Don't Spur HIV, Study Suggests
Calgary Herald Online (03/29/99)

Health Care Worker's Occupational Exposures
To Needle Sticks
Journal of the American Medical Association (03/99)

Almost 700 abstinence-only programs were established
last year by states using federal funding, according to the
Sexuality lnfonnation and Education Council of the United
States (SIECUS). A provision in the 1996 federal welfare
refonn bill will provide nearly $500 million of state and
federal funds for abstinence programs over five years.
SIECUS president Debra W. Haffner notes that the "influx of
money has influenced what infonnation young people are
receiving about sexuality," although the group adds that, in
general, most of the new programs did not replace other
"comprehensive" sex education measures.
In Georgia, Mississippi, Oklahoma, Indiana, and North
Carolina, there are now laws requiring abstinence-onlyuntil-marriage as the standard for students. According to
the SIECUS report, only two states -- California and New
Hampshire -- have not received funding through the
program, and 22 states have adopted abstinence-only
programs in schools.

A survey of 700 injection drug users in Vancouver
indicates that people who use needle-exchange programs
are not likely to increase high-risk behaviors for HIV. Dr.
Martin Schecter, lead author of the study, said that the
study would be helpful in generating support for the
programs. Schecter, of the University of British Columbia,
noted that opponents to needle-exchanges had been
using one of his previous studies to support their cause,
asserting that "people were quoting our study in [the U.S.]
Congress, using it to suggest that the needle exchange in
Vancouver made things worse." He added that he felt the
study - which concluded that the HIV rate was nearly
double among frequent users of exchanges compared to
infrequent users -- was being misinterpreted, and he
hopes that the present data will clear any confusion. While
needle exchanges help raise HIV awareness in
communities, said Schecter, other programs are needed
to properly combat the spread of the virus.

Cabin Fever Getting You Down?
Go Take a Hike!

Needle Program Doesn't Increase Crime
Baltimore Sun (03/30/99)

The AIDS Project and the University of New
England are teaming up to bring clients a
wonderful opportunity. Come enjoy the fresh air
and meet other people for student-led, easy/nonstrenuous walks and hikes around Cumberland
and York counties.
These free Outdoor-Wellness groups will be
happening once a month and will provide you
with a way to be outside in a safe and social
atmosphere, while getting some exercise and
enjoying the beautiful seacoast of Maine.
All those interested may call Denise at
985-8199 to sign up or to get more information.
Don't miss out on this great chance to meet
others, have fun, and see the beautiful sites of
southern Maine.
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Researchers from the Johns Hopkins School of Public
Health have found that a Baltimore needle-exchange
program has not contributed to drug-related crime or to
the number of discarded needles in the street. According
to the scientists, arrest patterns in areas with a needleexchange program did not differ significantly from
patterns in other parts of the city. Baltimore's health
commissioner, Dr. Peter Beilenson, said the study should
help address concerns that needle exchanges contribute
to the drug problem by sending a message that condones
drug use. Currently, Baltimore spends over $570,000 on
programs for intravenous drug use, including treatment
and needle exchanges. Beilenson said that the addition of
federal funding would allow the city's program, one of the
largest in the nation, to expand; however, a bill in the U.S.
Senate would pennanently ban the use of federal funds for
needle-exchange programs.

Alice Gemmer
Pamela W. Gleichman
Sandra Goolden
Celeste Gosselin
Jonathan W. Karol, D.0.
Leo J. LaPlante, CPA
Pamela Knowles Lawrason, Esq.
George M. Lord
Mallory K. Marshall
Mary Jean Mork
Gwendolyn C. O'Guin, D.0.
Patricia M. Pinto
Lois Galgay Reckitt
Victoria A . Rochefort
Lynn E. Shaffer
Elizabeth 0. Shorr
John H. Siegle, M.D.
Cynthia Sortwell, M.D.
Seth Sprague
James F. Tomney
Virginia W. Truesdale
Margaret Wiles
Jean T. Wilkinson
Margo Wintersteen
Roger F. Woodman
Frances R. Zilkha
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Researchers from Rush Medical College in Chicago and
the University of Colorado Health Sciences Center at Denver
analyzed HIV-1 genomes isolated from patients at a health
care clinic to detennine the prevalence of antiretroviral
resistance. The scientists sought to determine health care
workers' (HCW) risk of exposure to drug-resistant HIV
strains, perfonning genotypic analysis on 15 isolates taken
from individuals who were involved as source patients in
HCW occupational exposure. None of the patients had
received protease inhibitors, while 1Ohad taken zidovudine,
five didanosine, three lamivudine, two zalcitibine, two
stavudine, and one nevirapine. The researchers found a
high prevalence of antiretroviral resistance, with mutations
associated with reverse transcriptase therapy seen only in
patients who received antiretroviral therapy.
The authors note that the transmission of resistant HIV
strains has been reported, adding that "given the increasing
utilization of combination antiretroviral therapy, and the
growing number of patients harboring drug-resistant virus,
the potential exists for HCWs to become infected with
multidrug-resistant HIV through occupational exposure."
They suggest that patient treatment history may be helpful
in determining postexposure prophylaxis regimens for
exposed HCW's.

'Safe Needles' Urged to Protect Health Staff
Chicago Sun-Times Online (04/05/99)
Statistics from the Centers for Disease Control and
Prevention reveal that 1,800 needlestick accidents
occurred at six hospitals over a two-and-one-half-year
period. According to the CDC, there have been 45 confinned
HIV infections and 1,000 hepatitis B infections as a result of
needlesticks.
The risk of a health care worker contracting HIV from a
needle from an infected individual is one in 200. However, a
variety of new products aim to reduce that risk, including a
needle that automatically retracts after use.
In Illinois, the state House has approved a law requiring
public hospitals and clinics to use safe needles. The
measure, now pending in the state Senate, is opposed by
the Illinois Hospital and Health Systems Association, which
claims the government should allow the hospitals and
clinics to come up with their own solutions.

Addicts Wary of New Program
Portland Press Herald Online (03/14/99)
Maine's first needle-exchange program was launched in
January in an effort to keep the estimated 500 to 700
injection drug users in Greater Portland from contracting
and spreading HIV. While the Portland program received
widespread support in the community, organizers note that
the addicts themselves have been slow to accept the
exchange and only about a dozen IDU's are currently
enrolled. Organizers of the city's needle exchange program
say they anticipated the slow beginning and believe that
more IDU's will come to prevent infection.
The Portland needle exchange is funded by private
groups, certified by the state, and governed by strict federal
standards on biohazardous waste.
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Common Protein May Link Viruses
United Press International (03/25/99)

AIDS Researchers Target Poor Adherence
Journal of the American Medical Association (03/99)

Changing Trends in HIV-Related Morbidity Confirmed in
New York City
Reuters Health lnfonnation SeNices (03/29/99)

Research conducted at Northwestern University
indicates that there are similarities between the Ebola virus,
HIV, and the pathogens that cause measles, mumps, and
other infections. Scientists determined the structure of a
protein that the viruses use to enter host cells. The protein,
called the "fusion protein," snags the membrane of a host
cell, allowing the virus to enter the cell. The discovery,
which is documented in the March edition of Molecular
Cell, may help scientists develop antiviral medications.

Researchers at the Sixth Conference on Retroviruses
and Opportunistic Infections in Chicago presented
findings on HIV-infected patient adherence to medical
regimens. Using an electronic device called MEMScaps bottle caps containing microelectronics that measure and
record when the bottle has been opened ·· scientists from
the VA Medical Center in Pittsburgh and elsewhere found
that even patients who skipped only a few doses of highly
active antiretroviral therapy (HAARTI showed virologic
failure. According to the study results, decreasing
adherence was associated with increasing treatment
failure. The study also found that many patients
overestimated their adherence levels. Two other studies
determined that physicians did poorly in estimating
patient adherence. A survey of nationally representative
subjects showed that adherence was associated with
how well the regimen fit with the subject's daily lifestyle,
but that compliance was not correlated with the number
of pills taken or the number of medications prescribed.
Additionally, the survey showed poor adherence to be
associated with drug or alcohol use, while another study
indicated that untreated depression was associated with
decreased patient adherence.

Hit the Dirt
POZ(03/99)
New research indicates that the mineral selenium,
which is nontoxic at appropriate doses, could slow the
progression of HIV, possibly preventing viral replication.
University of Miami researchers found that seleniumdeficient HIV-infected subjects had a significantly increased
risk of death. The relative risk of death for deficient patients
was 20 times the risk for non-deficient patients, even after
adjusting for CD4 cell counts.
The researchers also found higher rates of death
associated with vitamin A, vitamin B-12, and zinc
deficiencies. The researchers are conducting a 328-person
trial to assess the effects of selenium administration on
disease progression.
Scientists Figure Out How
Immune System Remembers
Boston Globe (03/13/99)
Researchers from the University of Chicago have
discovered how the immune system "remembers" previous
attackers, a finding that could eventually lead to improved
vaccines and possibly treatment for HIV.
According to the scientists, who reported their findings
in the journal Science, the process by which memory cells
are produced is extremely slow. Following an attack by
viruses or cells that are starting to become cancerous, Tcells move quickly to the site and multiply; however, after a
time, the majority of the extra T-cells die off -and the few
cells that remain have a memory imprint of the attacker.
Yet, researcher Philip Ashton-Rickardt notes, that at least
five cycles of cell division are necessary for any of these
cells to develop, and it could be for this reason that no AIDS
vaccine to date has succeeded.
2 Human Proteins Isolated That Kill HIV, Report Says
Baltimore Sun (03/16/99)
Scientists have discovered that the urine of pregnant
women, as well as human tears and saliva, contains
proteins that have potent anti-HIV effects. The findings,
reported in the Proceedings of the National Academy of
Sciences, show that the protein lysozyme, a natural
compound that the body routinely produces and which is
found in human saliva and tears, killed HIV rapidly in testtube studies.
Another kind of protein, ribonucleases, which are found
in pregnant women's urine, was found to attack the genetic
material of HIV. New York University researcher Sylvia LeeHuang, a member of the team that identified the proteins'
abilities, speculated that drugs made from them could be
better tolerated and have fewer side effects than existing
HIV therapies.

Canada Approves AIDS Drug Sustiva
Reuters (03/23/99)
Canadian health authorities have approved the nonnucleoside reverse transcriptase inhibitor Sustiva for use
against HIV-1, reports manufacturer DuPont Co. Sustiva is
the first once-daily anti-HIV medication to be approved by
the Canadian Health Protection Branch.
Lipid Abnormalities Associated With Protease
Inhibitors
Journal of the Assoc. of Nurses in AIDS Care (03/99)
A team of researchers from Regions Hospital in St.
Paul, Minn., reports that protease inhibitor therapy for HIV
infection may result in high lipid levels in a large
percentage of patients. The scientists, led by N. Holly
Melroe, investigated lipid abnormalities in association
with three different protease inhibitor regimens in 136
HIV-patients.
Eighty percent of the patients on
norvir/saquinavir showed a significant increased in
cholesterol, as did 51 percent of patients on indinavir and
47 percent of patients on nelfinavir. An audit of patients
found that 91 percent of 40 patients on
ritonavir/saquinavir combination therapy had elevated
and abnormal cholesterol after the initiation of therapy.
Comparatively, 71 percent of patients on other protease
inhibitors showed similar results, while only 35 percent of
patients on non-protease inhibitor therapies and just 17
percent of patients not receiving therapy had elevated
cholesterol levels. The researchers note that extended use
of protease inhibitors may be risky and possibly have a
greater life-threatening potential than HIV infection itself
for some patients.

Researchers report in the February issue of AIDS that
there has been a decline in the number of HIV-related
hospital admissions and opportunistic infections in New
York City since the introduction of highly active
antiretroviral therapy (HAARTI. Researchers analyzed the
records of HIV-infected patients at the New York HospitalComell Medical Center during two six-month intervals: one
in 1995 - before HAART was available - and one in 1997.
The researchers determined that there was a significant
decrease in admissions, opportunistic infections, and death
among the 1,500 HIV-positive outpatients they followed
during the study. Median CD4 cell counts also increased
among patients during the study.
AIDS Fighters Pin Hopes on Immune Therapies
St. Louis Post-Dispatch Online (03/26/99)
Small-scale trials of anti-HIV drugs reported at the 11th
annual National HIV/AIDS Update Conference in San
Francisco show promise in the fight against AIDS.
Immune-based therapies, such as interleukin-2, Remune,
and GM-CSF. may help boost response to combination
therapy. lnterleukin-2 treatment in combination with antiretroviral drugs helped some subjects produce a prolonged
response, lasting almost two years in some patients.
Remune appears to help patients respond against multiple
HIV subtypes, while GM-CSF may aid in the clearance of
HIV from the body. None of the treatments have been
proven efficacious in large-scale trials, though, and
frequent side effects are a problem.
Initial HAART Discontinued at Rate of About 25 %Yearly
Reuters Health lnfonnation SeNices (03/25/99)
Dutch researchers report that each year about onequarter of patients who receive highly active antiretroviral
therapy (HAARTI discontinue their initial regimen. A study
published in the Journal of Acquired Immune Deficiency and
Human Retrovirology showed that of 99 patients followed
for 450 days, three patients withdrew from treatment and
27 patients altered their HAART regimen. Additionally, more
than 50 percent of patients with low CD4 + cell counts
discontinued initial treatment within one year. The authors
concluded that many patients discontinue initial HAART
treatment because of insufficient response to treatment or
due to side effects.
The Effect of Combination Antiretroviral Therapy Soon
After HIV Infection
Journal of Infectious Diseases Online (03/99)
Researchers from the Aaron Diamond Research Center
in New York, and others, investigated whether HIV-1 can be
cleared from infected individuals with the initiation of
lamivudine. zidovudine, and ritonavir therapy within 90
days of acute symptom onset. They treated 12 subjects and
found that viral replication was suppressed in adherent
subjects during the two-years of therapy. However, all
subjects showed the persistence of proviral DNA in
mononuclear cells. The authors also found a decrease in
HIV-1 specific antibodies and cytotoxic T lymphocyte
response in selected subjects. Vaccine strategies designed
to enhance these functions may be prudent before the
withdrawal of antiretroviral therapy, the researchers said.
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AIDS Drastically Cuts Life Spans in So. African Nations
Philadelphia Inquirer (03/19/99)

AIDS Still an Epidemic; Cases on Rise
MSNBC Online (03/16/99)

Quality of Life and Self-Care Management Strategies of
PLWA's With Chronic Diarrhea
Journal of the Association of Nurses in AIDS Care (03/99)

The U.S. Census Bureau reports that people in five
southern African nations have the shortest life spans in the
world - under 40 years -- due to high AIDS mortality rates.
Furthermore, Andrew Mutandwa, spokesman for the
Southern African AIDS Information Dissemination Service,
predicts that average life spans in Botswana, Zimbabwe,
Swaziland, Malawi, and Zambia will continue to decrease.
Prior to the AIDS epidemic, average life spans in the five
nations measured above 65 years. The census bureau also
reported that life spans in Ethiopia, Namibia, Rwanda, and
Uganda have fallen to under 45 years. The 21 countries with
the highest AIDS death rates in the world are in Africa, with
over two-thirds of the global AIDS population located in
Africa. Southern Africa has been most affected by AIDS,
which some experts believe is due in part to its extensive
highway system.

Research conducted by Stella Theodoulou, chair of the
political science department at California State University
at Northridge, indicates that the AIDS rate is continuing to
rise in some parts of the population in Los Angeles County.
Using data from 1982 through 1997, Theodoulou found
that rates are increasing substantially in certain
populations, including African-Americans, Hispanics, and
women. She said that media reaction to the disease
creates the impression that the epidemic will soon be
contained, which in tum misleads policy makers.

Scientists Say HIV Originates From
Long-Tailed Monkeys
Kyodo News SeNice (03/27/99)
Japanese scientists at Kyoto University report that HIV-1
could have originated in long-tailed monkeys in Africa. Last
January, U.S. researchers said they had found proof that
HIV-1 originated in chimpanzees, but the Japanese
researchers said they found viruses similar to HIV-1 in drills - which are similar to mandrills -- in central Africa. They
assert that the viruses are HIV-1 prototypes.
Miami's Black Clergy Prodded on AIDS
Miami Herald (03/16/99)
Speaking at a conference in Miami, Fla., the Rev. Jesse
Jackson challenged the Miami-area African-American
church community to increase its AIDS activism. Jackson
criticized fellow ministers for their reluctance to confront
the issue, urging ministers to get tested for HIV in a show of
leadership. AIDS is the leading cause of death among
African-Americans aged 25 to 44 and is the fourth leading
cause of death among all African-Americans in Florida.
Miami has the third highest AIDS rate among AfricanAmericans in major U.S. cities. There are an estimated
30,000 HIV-infected people in the Miami-Dade County area,
about 50 percent of whom are African American and onethird of whom are Hispanic.
Across the USA: Idaho
USA Today (03/22/99)
In Idaho, seven people in Idaho Falls and Pocatello have
recently been diagnosed with HIV. State health officials said
that the infected people probably contracted the virus from
heterosexual sex with different partners. They called the
outbreak a wake-up call to the region.
HHS Announces $710 Million in Grants for HIV/AIDS
U.S. Newswire (04/06/99)
In an effort to increase access to HIV/AIDS primary care
and related services, the U.S. Dept of HHS awarded formula
grants worth $710 million to the 50 states, the District of
Columbia, and the U.S. territories. State AIDS Drug
Assistance Programs will receive $461 million of the funds,
to help infected individuals buy HIV medications. HHS
Secretary Donna E. Shalala said, "These grants reaffirm the
administration's commitment to provide vital HIV/AIDS
health care to communities most in need."

Advertising The Facts About AIDS
New York Times (03/17/99)
The American Foundation for AIDS Research (Amfar)
and the advertising agency Young and Rubicam will team
up in an effort to fight public complacency on AIDS issues.
Amfar is also trying to raise donation levels by $4 million to
$22 million a year. Young and Rubicam, Cato Johnson,
Landor Associates, Burson-Marsteller, and Kenneth Cole
Productions will all contribute to the campaign. In all,
television and radio networks will contribute over $2
million in commercial time and ad space. Amfar and Young
and Rubicam seek an additional $3 million in ad space and
commercial time.

HIV Treatment News
Elective Caesarean-Section Versus Vaginal Delivery in
Prevention of Vertical HIV-1 Transmission"
lancet (03/27/99)
The European Mode of Delivery Collaboration
conducted randomized clinical trials to assess possible
vertical HIV transmission risk-reduction associated with
caesarean-section delivery. The researchers assigned
eligible HIV-positive pregnant women for either elective
caesarean delivery or for vaginal delivery. Of 370 infants
born to the women, 170 infants were born to women
assigned to the elective caesarean-section delivery
group. Three of these children (1.8 percent) were found to
be HIV-positive by age 18 months. Comparatively, 21 of
the 200 children (10.5 percent) born to women designated
for vaginal delivery were HIV-positive after 18 months.
Seven of 203 infants (3.4 percent) who were actually
delivered through caesarean section contracted HIV,
while 15 of 167 (10.2 percent) of children delivered
vaginally contracted the virus.
The researchers conclude that "elective cesareansection delivery significantly lowers the risk of mother-tochild transmission of HIV-1." They add that few
postpartum complications and no serious side effects
were observed among any of the women.

Researchers from the University of California, San
Francisco, surveyed 20 people living with AIDS (PLWA's)
who reported chronic diarrhea and 20 PLWA's without
chronic diarrhea to analyze quality of life issues associated
with diarrhea in AIDS patients. Diarrhea often results from
pathogens, such as cryptosporidium and isoporabelli, and
medications, such as antibiotics and nucleoside reverse
transcriptase inhibitors. The researchers, led by Suzanne
Bakken Henry, found that PLWA's without chronic diarrhea
reported significantly higher general health perceptions.
They also reported increased fatigue, greater psychological
distress, and greater gastrointestinal discomfort.
The majority of patients with chronic diarrhea used
dietary supplements, vitamins, and medications for selfmanagement of their digestive problems. However, only 40
percent reported following a special diet and one-quarter
said they used herbs to treat the diarrhea. Some common
dietary restrictions included the avoidance of caffeine,
sorbitol, alcohol, and insoluble fiber, with the limitation of fat
and lactose intake.
PLWA's with chronic diarrhea also reported significant
pain (60 percent of respondents), weight loss greater than
10 pounds (45 percent), decreased social activity (45
percent) and decreased sexual activity (20 percent). The
authors conclude that the quality of life limitations created
by chronic diarrhea support the need for symptom
management interventions.
Factors Associated Wrth Refusal to Treat HIV-Infected
Patients: The Results of a National Survey of Dentists in
Canada
American Journal of Public Health (04/99)
Researchers from the University of Western Ontario
conducted a survey of dentists in Canada to assess the
percentage of care providers who refuse to treat HIVinfected patients. Of 4, 107 respondents, 16 percent said
they would refuse treatment to HIV-positive patients.
Treatment refusal was most strongly associated with lack
of belief in an ethical responsibility to treat infected
patients, while staff fears, patient loss, cost of infection
control, and safety concerns also played a role.
Overall, 81 percent of dentists said they would treat HIVpositive patients, with 86 percent reporting that they would
treat injection drug users, and 87 percent replying that they
would treat patients infected with hepatitis B virus. Ninetyfour percent of respondents would treat homosexual and
bisexual patients, while 94 percent said they would treat
people with sexually transmitted diseases, and 97 percent
said they would treat recipients of blood and blood
products. Almost one-third of respondents said they had
knowingly treated an HIV-infected patient within the prior
year. Current Canadian Dental Association guidelines state
that dentists must not refuse patients solely on the grounds
of HIV infection.

Men's Health Project· Sanford, Yark County
Thursday Evenings. 7-9 p.m., Sanford, Maine. May 6-June 24, 1999 (transportation available)

Are you a man who has gay sex, and may or may not call yourself ' gay'? Are you just 'coming out', but dont wantto be labeled? Are you
perhaps married? Are you already out, but want to meet other men to relate around healthy sexuality, relationships, and other issues?
You (especially TAP clients) are invited to a free, totally confidential, eight-week program for men who have sex with men, regardless of
age, marital status, or HIV status. The group will be led by two professional health educators from The AIDS Project's Men's Wellness
Program. All we ask is that you pre-register (confidentiality assured) and agree to come to all 8 sessions. The group meets at a downtown
Sanford location, every Thursday evening in May and June from 7to 9 p.m. First meeting: May 6th.
To register, call Geny at (207) 774-6877 or 1-800-851-2437.
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IN THE AFFIRMATIVE
PRO.JECT

SUPPORT GROUPS
FOR PEOPLE INFECTED
AND AFFECTED BY HIV/AIDS

MONDAYS
Time: 5:00 p.m. to 6:30 p.m.
Group: HIV and Substance Abuse
Location: Portland, The Meeting Room, Suite 632.
Contact Carolyn Curtis at TAP at 774-6877, or David
Gordon at Portland Public Health at 874-8784.

TUESDAYS
Time: 10:30 a.m. to noon
Group: HIV Infected/Affected Drop-In Support Group
A meeting for people living with and affected by the virus.
Location: Portland, TAP. The Meeting Room, Suite 632.
Contact Susan Parr atTAP at 774-6877 for more info.

THURSDAYS

PRO.JECT

CLIENT SERVICES
MEDICAL ASSISTANT FUNDS
An important reminder to clients:
There are funds available to TAP clients with financial need
for the following items: Routine Dental Care, Routine Eye
Care and Eyeglasses, Vitamin Supplements, NonPrescription Skin Care Products, and Non-Medicaid
Medication Co-pays.
There is a dollar limit to how much a client can receive in any
fiscal year. Contact your case manager for assistance.

IMMEDIATE SEATING
For free tickets to area events as they become available,
sign up for "Immediate Seating." Call Daniel at TAP at 7746877 for more information.

I.V. LEAGUE
Meetings of the I.V. League support group are held on
Thursdays from 10:00 to 11 :30 a.m. at First Parish Church
at 425 Congress St. in Portland. (Use the right side entrance
and ring the bell)
For more information, call Steve Farrell at 874-8775.

Time: 10:00 a.m. to 11 :30 a.m.
Group: HIV Infected/Affected Drop-in Group
A TAP-sponsored meeting for people
living with and affected by HIV/AIDS in southern Maine.
Location: Sanford, Unitarian Church, located at the comer of
MainSt.(Rte. 109)andLebanonSt.(Rte. 202).
THE MEETING ROOM
ContactGettyPaysonatTAPat985-8199formoreinfo.
This room is used by TAP in Portland for support groups,
counseling and testing, and some client/case manager
Time: 12 noon
meetings. Located in Suite 632, it provides more privacy for
Group: Open Lunch for TAP Clients/Staff
people served by TAP.
An informal luncheon gathering ofTAP staff and clients.
Enter from the High Street side of the building.
Location: Portland, TAP. Conference Room.
Contact Daniel Schnorbus at TAP at 77 4-6877 for info.
Time: 5:30 p.m. to 7:00 p.m.
Group: People Living with HIV/AIDS
A drop-in support group for anyone with HIV/AIDS.
Location: Portland, TAP. The Meeting Room, Suite 632.
Contact Susan Parr at TAP at 774-6877 for more info.

>>>>New Group<<<<

FOR YOUR INFORMATION
TAP ON-LINE
Visit our new website at: www.aidsprojact.org
To e-mail The AIDS Project,
send your message along to:
tap@aidsprojact.org (Portland)
or tap2@mail.javanat.com (Kennebunk)

In The Affirmative is a monthly
newsletter published by The AIDS
Project for people living with and
affected by HIV/AIDS. Letters, articles,
or other submissions should be sent to:
In The Affirmative, c/o The AIDS
Project, P.O. Box 5305, Portland, ME
04101, or call (207) 774-6877.
Submissions can be printed anonymously as long as the person submitting the material includes his or her
name and phone number for verification.
News, information, and features are
as up-to-date as possible prior to
publication. Any medical information
included in this newsletter is submitted
for the reader's information only, to be
used as the reader so chooses.

Sources for some of the information
in this newsletter include:
CDC HIV/STD/TB Prevention
News Update
Contributors include:

Whan: Day and Time to be announced
Group: Expressive Therapy
HIV WEBSITES
Explore your creativity through art, music, movement.
Location: Portland, The Meeting Room, Suite 632.
Check out these websites:
Contact Susan Parr at TAP at 774..{;877 for more info. www.hivpositiva.com
_ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ www.thabody.com
www.projinf.org
York County Clients
for info on HIV and AIDS.

Denise Ferer
Demetra Giatas
Sandy Putnam
Daniel Schnorbus
Gerry Scoppettuolo

York County Clients of TAP can use the computer at its
Ai DS HOTLINE$
Kennebunk office to access the internet. Call Getty
Questions about HIV/AIDS?
Payson at 985-8199 to set up a time to use the computer. Call toll-free

People Art © David Cedrone

National AIDS Hotline:
1-800-342-2437
Maine AIDSline:
- - - - - - - - - - - - - - - - 1-800-851-2437
Also, clients can now e-mail TAP's Kennebunk office at:
www.tap2@mail.javanat.com

WELLNESS AND YOU PROGRAM
A stress reduction and physical activity program
designed for people living with HIV/AIDS. In this program
individuals can participate in a variety of supervised
physical activity, education, and specialized stress
management segments. Contact Daniel at TAP at 7746877 for more information.

Kerry S. Tardiff, Distribution
Mike Martin, Editor

Maine Teen Hotline:
1-800-851-2437
(on Wednesdays from 6-9pm)

For more infonnation about programs
The AIDS Project, call Susan Parr, TAP's
Support Group Manager, at 774-6877.
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